Author's response to reviews

Title: The Management of Bipolar Mania: a national survey of Baseline data from the EMBLEM study in Italy

Authors:

Cesario Bellantuono (Cesario.bellantuono@univr.it)
Alessandra Barraco (barraco_alessandra@lilly.com)
Andrea Rossi (rossi_andrea_a@lilly.com)
Iris Goetz (goetz_iris@lilly.com)

Version: 4 Date: 1 March 2007

Author's response to reviews: see over
**Subject: Revised version of the manuscript by Bellantuono et al**

Dear Editor,

Please find enclosed a revised version of the paper about the study entitled “The Management Of Bipolar Mania: A National Survey Of Baseline Data From The Emblem Study In Italy” by Bellantuono et al.

Reviewers comments have been addressed as follows:

**Reviewer Michael J Ostacher:**

**Minor Essential Revisions**

Q: Reviewer:
Use "minority" rather than "minor" on page 13.
A: The substitution was performed as requested

**Discretionary Revisions (which the author can choose to ignore)**
The low lifetime rate of suicide attempt is probably related to the relatively late onset of bipolar illness, as earlier age of onset is associated with a greater likelihood of having made a suicide attempt.
A: This possibility has added in the discussion

**Reviewer: George Kirov**

**Minor Essential Revisions**

Q: Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)
The fact that the study was sponsored by Eli Lilly (the manufacturer of Olanzapine) and that the psychiatrists received honoraria for recruiting patients, should be stated in the "Competing Interest" and the "Methods" sections.
A: Methods and competing interest sections modified as requested